A new study published by the journal Neurochemical Research, and published online by the U.S. National Institute of Health, has confirmed past research that shows cannabidiol to be an anti-seizure agent.
For the study; “The National Institute of Neurological Disorders and Stroke (NINDS) funded Epilepsy Therapy Screening Program (ETSP) investigated CBD in a battery of seizure models using a refocused screening protocol aimed at identifying pharmacotherapies to address the unmet need in pharmacoresistant epilepsy”.
Applying this new screening workflow, CBD was investigated in multiple mouse and rat models of acute seizures. Following intraperitoneal (i.p.) pretreatment, “CBD produced dose-dependent protection in the acute seizure models.” In chronic models, “CBD produced dose-dependent protection in the corneal kindled mouse”.
Motor impairment assessed in conjunction with the acute seizure models “showed that CBD exerted seizure protection at non-impairing doses.”
Researchers conclude that; “The ETSP investigation demonstrates that CBD exhibits anti-seizure properties in acute seizure models and the corneal kindled mouse.”
However, the study notes that “further preclinical and clinical studies are needed to determine the potential for CBD to address the unmet needs in pharmacoresistant epilepsy.”
The full study – conducted by researchers at the National Institute of Health, the University of Utah and the University of California San Fransisco – can be found by clicking here.